James Reynolds

James D. Reynolds

James D. Reynolds MD

UBMD Ophthalmology at the Ross Eye Institute


Ophthalmology; Pathophysiology; Pediatric Ophthalmology; Retina; Vision science

Accepting new patients

Professional Summary:

Dr. Reynolds has various research interests in pediatric ophthalmology, but his main niche is retinopathy of prematurity. ROP is a disease of the developing immature retinal vasculature, modulated by hyperoxia/hypoxia micro environments in the retina, which can lead to neovascularization, scarring, and potential blindness. Dr. Reynolds is a recognized expert in the field and is the author of many peer reviewed articles and several invited review chapters. His NIH funding has been nearly continuous while at U.B. while participating in several multi-center clinical trials in ROP as center P.I. and project director.

Dr. Reynolds was the center P.I. at U.B. for the first large treatment trial for ROP, CRYO-ROP. This trial established the first known effective treatment for this high socioeconomic impact disease. As center P.I. he participated in the group collaborative publications as well as co authoring many individually by-lined papers (Ref. 22, 23, 24, 25, 26, 28, 29, 31, 32, 37, 40, 42). His successful and productive work as a center P.I. on this trial led to the funding for the LIGHT-ROP multi-center trial for which he served as project director and lead P.I. This trial definitively answered a long debated hypothesis in ROP i.e. that ambient light was not a causal factor in ROP (Ref. 38, 41, 45, 47). Dr. Reynolds was again selected as a center P.I. for the next large multi-center ROP trial, ET-ROP, which just reported its primary results demonstrating that earlier laser treatment for this disease was effective.

Although all multi-center clinical trials are cooperative agreements at the NIH and thus are funded as UO1s rather than RO1s, Dr. Reynolds was an integral participant in all the ROP trials from the mid-eighties to the present, leading one, and actively co-authoring many of the studies?publications as noted in the bibliography. The future of Dr. Reynolds?ROP research will undoubtedly involve more funded multi-center trials. However, a basic science collaboration into the pathophysiology of ROP in an animal model is planned, investigating the renin-angiotension connection.


Ophthalmology, Pathophysiology, Pediatric Ophthalmology, Retina, Vision science

Patients Treated:

Children, Adolescents

Physician Gender:



UBMD Ophthalmology: Ross Eye Institute
Ross Eye Institute Amherst Location
3580 Sheridan Drive #150
Buffalo, New York 14226
Office Hours: Wednesday 8:30 - 3:30
Phone: 716-881-7900
Fax: 716-881-4349
Contact: Elaine Taylor
Accepting new patients

Insurance Accepted:
  • Aetna U.S. Healthcare
  • Blue Cross & Blue Shield of WNY Inc
  • CIGNA HealthCare
  • Community Blue (HMO)
  • Fidelis
  • GHI
  • Independent Health Association (HMO)
  • Medicaid
  • North American Administrators
  • Tricare
  • United Healthcare
  • Univera Health Care (HMO)

Board Certifications:

  • Board Certification, American Board of Ophthalmology

Education and Training:

  • Fellowship, Pediatric Ophthalmology, University of Pittsburgh (1982)
  • Ophthalmology, SUNY/Buffalo (1981)
  • MD, SUNY/Buffalo (1978)
  • BA, Biology, SUNY/Buffalo (1974)

Awards and Honors:

  • Named to Business First 2008 Healthcare 50 (2008)
  • Vision of Light Award for Distinguished Service (1996)
  • WNY Top Doctors. Spree Magazine
  • America‘s Top Doctors

Research Profile:

This UBMD physician is also a member of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, teaching the next generation of doctors and researching to advance care in WNY and beyond. Learn more about this physician's research and teaching activities, as well as view credentials, publications, professional involvement and more below.

UBMD News: